Rigontec is a leading company in the immune-oncology field developing compounds interacting with RIH-I receptor. The company was acquired August 2017 by MSD for up to EUR 463 million.
Location: Germany, Bavaria, Planegg
Employees: 51-200
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | Forbion | forbion.co... |
Mentions in press and media 5
| Date | Title | Description |
| 07.09.2017 | Term Sheet — Thursday, September 7 | SPORTS TALK Good morning, Term Sheet readers. Paid Content What you need to know about growing cyberattacks From ExtraHop The company also announced a strategic investment and partnership with the NFL Players Association through the OneTeam... |
| 06.09.2017 | MSD to acquire Rigontec | MSD today announced the acquisition of Rigontec for up to US$553M |
| 03.05.2017 | Rigontec starts FIH Phase I/II trial of RIG-I agonist RGT100 & appoints new CMO | Rigontec today announced the dosing of the first patient in a phase I/II study with intratumoral/intralesional administration of its lead compound RGT100 in solid tumors and lymphoma. In addition, Rigontec appoints industry veteran Prof. Eu... |
| 14.11.2016 | Rigontec appoints new CSO | Rigontec Appoints Dr. Jörg Vollmer as Chief Scientific Officer |
| - | Rigontec Raises Additional €15M in Extended Series A to Advance Novel RIG-I Targeted Immuno-Oncology Therapeutics | Rigontec, the leader in RIG-I targeting RNA therapeutics, today announced that it has secured EUR 15 million in a third and final closing of its Series A round. The financing represents additional capital from current investors Boehringer I... |